Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan in Reflux Esophagitis
NCT05813561Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in reflux esophagitis, sponsored by Daewoong Pharmaceutical. Started Dec 2021; status: completed.
02
Drugs
fexuprazan
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT05813561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813561.